Kuriyama K, Murakami K, Sugiura K, Sakui S, et al. One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial. Vaccine 2024 Feb 2:S0264-410X(24)00068-9. doi: 10.1016/j.vaccine.2024.
PMID: 38310018